Literature DB >> 16365687

Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis.

Eishi Miyazaki1, Masaru Ando, Tomoko Muramatsu, Tetsujiro Fukami, Osamu Matsuno, Shin-Ichi Nureki, Takuya Ueno, Tomiyasu Tsuda, Toshihide Kumamoto.   

Abstract

Amyopathic dermatomyositis (ADM) is occasionally complicated by rapidly progressive interstitial pneumonia (RPIP), and in such cases, diffuse alveolar damage (DAD) is usually diagnosed at autopsy. Here, we present three patients with RPIP accompanied by ADM in whom lung disease was assessed at an early stage. High-resolution computed tomography (HRCT) carried out before the onset of dyspnoea revealed uniformly subpleural reticular opacity with faint ground-glass attenuation. At that stage, surgical lung biopsies from two patients showed histological patterns typical of cellular nonspecific interstitial pneumonia (NSIP). Despite pulse methylprednisolone and subsequent high-dose oral administration of prednisolone, lung disease progressed in all patients, with extensive areas of ground-glass opacity and consolidation observed in HRCT scans. DAD was confirmed histologically in one case. Additional administration of cyclosporine, pulse cyclophosphamide or high-dose intravenous administration of immunoglobulin rescued all patients. Our data suggest that ADM-associated interstitial pneumonia takes an aggressive course even when the radiological and histological features are consistent with NSIP. Aggressive combination therapy with high-dose steroids and immunosuppressive agents is required as early as possible for patients with this life-threatening disorder.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16365687     DOI: 10.1007/s10067-005-0147-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

Review 1.  Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis.

Authors:  Richard D Sontheimer; Sachiko Miyagawa
Journal:  J Am Acad Dermatol       Date:  2003-05       Impact factor: 11.527

2.  Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP.

Authors:  S Nagai; M Kitaichi; H Itoh; K Nishimura; T Izumi; T V Colby
Journal:  Eur Respir J       Date:  1998-11       Impact factor: 16.671

3.  Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings.

Authors:  H D Tazelaar; R W Viggiano; J Pickersgill; T V Colby
Journal:  Am Rev Respir Dis       Date:  1990-03

4.  Acute interstitial pneumonia: thin-section CT findings in 36 patients.

Authors:  T Johkoh; N L Müller; H Taniguchi; Y Kondoh; M Akira; K Ichikado; M Ando; O Honda; N Tomiyama; H Nakamura
Journal:  Radiology       Date:  1999-06       Impact factor: 11.105

5.  Dermatomyositis without creatine kinase elevation. A poor prognostic sign.

Authors:  E J Fudman; T J Schnitzer
Journal:  Am J Med       Date:  1986-02       Impact factor: 4.965

6.  Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients.

Authors:  P Cherin; S Herson; B Wechsler; J C Piette; O Bletry; A Coutellier; J M Ziza; P Godeau
Journal:  Am J Med       Date:  1991-08       Impact factor: 4.965

7.  Idiopathic inflammatory myopathy with diffuse alveolar damage.

Authors:  C-S Lee; T-L Chen; C-Y Tzen; F-J Lin; M-J Peng; C-L Wu; P-J Chen
Journal:  Clin Rheumatol       Date:  2002-09       Impact factor: 2.980

8.  Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients.

Authors:  M Akira; H Hara; M Sakatani
Journal:  Radiology       Date:  1999-02       Impact factor: 11.105

9.  Acute interstitial pneumonia: radiographic and CT findings in nine patients.

Authors:  S L Primack; T E Hartman; J Ikezoe; M Akira; M Sakatani; N L Müller
Journal:  Radiology       Date:  1993-09       Impact factor: 11.105

10.  Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis.

Authors:  M al-Janadi; C D Smith; J Karsh
Journal:  J Rheumatol       Date:  1989-12       Impact factor: 4.666

View more
  15 in total

1.  Evaluation and management of pulmonary disease in ataxia-telangiectasia.

Authors:  Sharon A McGrath-Morrow; W Adam Gower; Cynthia Rothblum-Oviatt; Alan S Brody; Claire Langston; Leland L Fan; Maureen A Lefton-Greif; Thomas O Crawford; Michelle Troche; John T Sandlund; Paul G Auwaerter; Blaine Easley; Gerald M Loughlin; John L Carroll; Howard M Lederman
Journal:  Pediatr Pulmonol       Date:  2010-09

2.  Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients.

Authors:  Yuechi Sun; Yuan Liu; Bing Yan; Guixiu Shi
Journal:  Rheumatol Int       Date:  2012-11-10       Impact factor: 2.631

3.  Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.

Authors:  Shuang Ye; Xiao-xiang Chen; Xiao-ye Lu; Mei-fang Wu; Yun Deng; Wen-qun Huang; Qiang Guo; Cheng-de Yang; Yue-ying Gu; Chun-de Bao; Shun-le Chen
Journal:  Clin Rheumatol       Date:  2007-02-17       Impact factor: 2.980

4.  Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis.

Authors:  Yuzo Suzuki; Hiroshi Hayakawa; Seiichi Miwa; Masahiro Shirai; Masato Fujii; Hitoshi Gemma; Takafumi Suda; Kingo Chida
Journal:  Lung       Date:  2009-04-22       Impact factor: 2.584

Review 5.  Pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis with cryptogenic organizing pneumonia in invasive breast cancer: a case report and review of literature.

Authors:  Sung Hwan Park; Yoon-Seup Kum; Kyung-Chan Kim; Jung-Yoon Choe; Sung-Hoon Park; Seong-Kyu Kim
Journal:  Rheumatol Int       Date:  2008-12-18       Impact factor: 2.631

Review 6.  Management of connective tissue diseases associated interstitial lung disease: a review of the published literature.

Authors:  Beth Wallace; Dharshan Vummidi; Dinesh Khanna
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

7.  Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis.

Authors:  Fang Chen; Dongxue Wang; Xiaoming Shu; Ran Nakashima; Guochun Wang
Journal:  Rheumatol Int       Date:  2011-12-25       Impact factor: 3.580

8.  Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine.

Authors:  Masaru Ando; Eishi Miyazaki; Mari Yamasue; Yukiko Sadamura; Toshihiro Ishii; Ryuichi Takenaka; Takeo Ito; Shin-ichi Nureki; Toshihide Kumamoto
Journal:  Clin Rheumatol       Date:  2010-02-04       Impact factor: 3.650

9.  A Case of Polymyxin b-Immobilized Fiber Column Treatment for Rapidly Progressive Interstitial Pneumonia Associated with Clinically Amyopathic Dermatomyositis.

Authors:  Oh Sasaki; Makoto Dohi; Hiroaki Harada; Mitsuru Imamura; Yumi Tsuchida; Kensuke Yamaguchi; Toshihiko Komai; Kazuhiko Yamamoto
Journal:  Case Rep Med       Date:  2013-07-28

10.  Pre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute/subacute interstitial pneumonia in dermatomyositis treated by cyclosporine a/glucocorticosteroid combination therapy: a case control study [corrected].

Authors:  Kentaro Isoda; Tohru Takeuchi; Takuya Kotani; Kenichiro Hata; Takeshi Shoda; Takaaki Ishida; Shuzo Yoshida; Yuko Kimura; Shigeki Makino; Toshiaki Hanafusa
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.